Assuntos
Dor Abdominal/etiologia , Adenocarcinoma/cirurgia , Cistadenoma Seroso/cirurgia , Neoplasias das Tubas Uterinas/cirurgia , Procedimentos Cirúrgicos em Ginecologia/métodos , Laparoscopia/métodos , Neoplasias Ovarianas/cirurgia , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Adulto , Idoso , Antinematódeos/uso terapêutico , Cistadenoma Seroso/tratamento farmacológico , Cistadenoma Seroso/patologia , Neoplasias das Tubas Uterinas/tratamento farmacológico , Neoplasias das Tubas Uterinas/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia , Resultado do TratamentoRESUMO
OBJECTIVE: The aim of this study was to investigate the effects of two currently used low-dose combined oral contraceptives (COCs) (20 µg ethinyl estradiol [EE]/150 µg desogestrel [DSG] vs. 20 µg EE/100 µg levonorgestrel [LNG]) on plasma homocysteine levels. METHODS: A total of 90 participants were enrolled in the study; 30 of them had not been using COC for at least 12 months prior to their enrollment, while 60 were on regular treatment within 12-18 months. Therefore, the control group consisted of 30 participants. Group DSG/EE consisted of 30 women and group LNG/EE consisted of 30 women. Serum samples of homocysteine profile were obtained during the early follicular phase. RESULTS: Significantly lower serum homocysteine concentrations (Group DSG/EE: 7.2 +/- 1.3; Group LNG/EE: 9.1 +/- 3.2; CONTROL GROUP: 8.2 +/- 2.2; p<0.05) were observed in DSG/EE group compared to LNG/EE and control groups. CONCLUSION: Although the decrease in homocysteine levels with 20 µg EE/150 µg DSG containing COC was statistically significant, the clinical relevance of our findings needs to be further investigated.